Continuous Renal Replacement Therapy Market Size Estimated to Reach $1811.5 Million by 2026

sneha Patel

65
views

Continuous Renal Replacement Therapy Market Size Estimated to Reach $1811.5 Million by 2026

Continuous Renal Replacement Therapy Market size is estimated to reach $1811.5 million by 2026, growing at a CAGR of 8% over 2021-2026. Continuous renal replacement therapy (CRRT) are used for renal support for the patients with acute kidney injury (AKI). The Continuous renal replacement therapy (CRRT) therapy is carried for 24 hours through the process of hemodialysis or hemofiltration or both methods are used.

Continuous Renal Replacement Therapy Market Overview

Various other therapy such as slow continuous ultrafiltration (SCUF) helps to eliminate excessive fluid from the bloodstream via ultrafiltration where dialysate or replacement fluid are not used. Increasing incidence of acute kidney injury and chronic kidney disease and growing technological advancement is the major factor driving the growth of this market. Furthermore, increasing research and development activities in medical industry and increasing initiatives by the government for the development in healthcare sector is set to further enhance the overall market demand for Continuous Renal Replacement Therapy Market for the period 2021-2026.

Report Coverage

The report: “Continuous Renal Replacement Therapy Market Forecast (2021-2026)”, by IndustryARC, covers an in-depth analysis of the following segments of the Continuous Renal Replacement Therapy Market.

By Product: Systems, and Consumables.

By Modality: Slow Continuous Ultrafiltration (SCUF), Continuous Venovenous Hemofiltration (CVVH), Continuous Venovenous Hemodialysis (CVVHD), and Continuous Venovenous Hemodiafiltration (CVVHDF).

By Geography: North America (U.S., Canada, Mexico), Europe (U.K, Germany, Italy, France, Spain, Russia, Rest of Europe), Asia Pacific (China, Australia, Japan, South Korea, India, Rest of Asia Pacific), South America (Brazil, Argentina, Others) and Rest of the World (Middle East, Africa).

Key Takeaways

Geographically, in 2020, North America dominated the Continuous Renal Replacement Therapy Market owing to increasing demand for CRRT procedures and radical innovation of the machine and systems and rising prevalence of kidney disease.
The demand for Continuous Renal Replacement Therapy is set to increase as the frequency of acute kidney injury and chronic kidney disease rises, as well as technological advancements.
Detailed analysis of the Strength, Weakness, and Opportunities of the prominent players operating in the market will be provided in the Continuous Renal Replacement Therapy Market report.
High cost of CRRT procedure is set to create hurdles for the Continuous Renal Replacement Therapy Market.

Continuous Renal Replacement Therapy <span lang="EN-US" calibri","sans-serif";mso-ascii-theme-font:minor-latin;="" mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:minor-latin;color:black;="" mso-themecolor:text1;mso-font-kerning:12.0pt;mso-ansi-language:en-us"="" style="box-sizing: border-box;">Market Size, By Modality <span lang="EN-US" calibri","sans-serif";mso-ascii-theme-font:minor-latin;="" mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:minor-latin;color:black;="" mso-themecolor:text1;mso-font-kerning:12.0pt;mso-ansi-language:en-us"="" style="box-sizing: border-box;">2020-2026 (USD Million)

Continuous Renal Replacement Therapy Market

For More Details on This Report - Request for Sample

Continuous Renal Replacement Therapy Segment Analysis – By Product

The global Continuous Renal Replacement Therapy Market based on Product can be further segmented into Systems, and Consumables. The Systems segment is the major segment generating revenue in 2020. This is mainly owing to increasing prevalence of acute kidney injury cases. Furthermore, the prevalence of acute kidney injury treated with CRRT is approximately 200-300 per million, according to the National Center for Biotechnology Information, which increases the use of these systems and the market's growth.

The Consumables segment is estimated to register the fastest CAGR of 2.5% for the period 2021-2026. This is primarily owing to an increase in the use of consumables due to their low cost, as well as an increase in the use of charcoal filters, hemofilters, and fluids, which are all contributing to the market's growth.

Continuous Renal Replacement Therapy Segment Analysis – By Modality

The global Continuous Renal Replacement Therapy Market based on Modality can be further segmented into Slow Continuous Ultrafiltration (SCUF), Continuous Venovenous Hemofiltration (CVVH), Continuous Venovenous Hemodialysis (CVVHD), and Continuous Venovenous Hemodiafiltration (CVVHDF). The Continuous Venovenous Hemofiltration (CVVH) segment registers for the highest Continuous Renal Replacement Therapy market share in 2020. This is owing to the rising occurrence of fluid overload cases in patients with acute kidney disease in critical care units, which is fueling the market's growth. The Continuous Venovenous Hemodiafiltration (CVVHDF) segment is estimated to register the fastest CAGR of 1.5% over 2021-2026. This is mainly owing to this treatment modality results in the replacement of solutes and fluids within the blood that increase the growth of this market.

Continuous Renal Replacement Therapy Segment Analysis – By Geography

North America dominated the Continuous Renal Replacement Therapy Market with major share of 40% in 2020. This is owing to increasing demand for CRRT procedures and radical innovation of the machine and systems and rising prevalence of kidney disease. According to the Centers for Disease Control and Prevention (CDC), 34.2 million people in the United States are diagnosed with diabetes in 2020, and this will increase the demand for slow continuous ultrafiltration and drive market growth. However, Asia Pacific is estimated to outpace all the regions by clocking the highest CAGR of 4% during the forecast period 2021-2026 owing to increasing geriatric population and improvement in healthcare centers.

Continuous Renal Replacement Therapy Market Drivers

Increasing Incidence of Acute Kidney Injury

The increasing incidence of acute kidney injury and chronic kidney disease are increasing the growth of the Continuous Renal Replacement Therapy Market. According to International Diabetes Federation, in 2019 about 463 million people have diabetes that increases the number of patients with acute kidney disease and are increasing the growth of the Continuous Renal Replacement Therapy Market over 2021-2026.

Growing Technological Advancement

Increasing innovation in technology increases the use of CRRT for the management of acute kidney injury that increases the growth of this Market. Moreover, technological advancement expanded the field of extracorporeal therapies in the ICU that increasing the growth of Continuous Renal Replacement Therapy Market over 2021-2026.

Covid-19 Impact:

COVID-19 pandemic had greatly affected the Continuous Renal Replacement Therapy Market. During pandemic, researcher’s disclose that kidney infections are intervened by excessive immune response observe in severe COVID-19 patients that increases the treatment of hemodialysis and hemofiltration that are positively impacted the growth of this market.

Continuous Renal Replacement Therapy Market Challenges

High Cost of CRRT Procedure

The factors that is set to impede the growth of the Continuous Renal Replacement Therapy Market are the high cost of CRRT procedure. Moreover, stringent regulatory procedures is set to create hurdles for the Continuous Renal Replacement Therapy Market.

Continuous Renal Replacement Therapy Landscape

Product launches, mergers and acquisitions, joint ventures, and geographical expansions are key strategies adopted by players in the Continuous Renal Replacement Therapy Market. Continuous Renal Replacement Therapy top 10 companies include, B. Braun Melsungen AG, Baxter International, Inc., Fresenius Medical Care AG & Co. KGaA, Asahi Kasei Corporation, NIPRO Corporation, Toray Medical Co., Ltd, NxStage Medical, Inc., Medtronic plc, Baxter and Nikkiso Co.

Developments

In March 2019, Baxter International Inc. cleared its PrisMax system and the integrated TherMax blood warmer for continuous renal replacement therapy.
In February 2019, Fresenius Medical Care AG & Co. KGaA has acquisition with NxStage Medical, Inc. in order to develop the new device for continuous dialysis.